Health state utilities in patients with diabetic retinopathy, diabetic macular oedema and age-related macular degeneration: A systematic review

BMC Ophthalmology

Volumn 13, Issue 1, 2013, Pages

  Poku, Edith ^a   Brazier, John ^a   Carlton, Jill ^a   Ferreira, Alberto ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Age related macular degeneration; Diabetic retinopathy; Health utility; Visual acuity

Indexed keywords

DIABETIC RETINOPATHY; ECONOMICS; HEALTH STATUS; HEALTH STATUS INDICATOR; HUMAN; RETINA MACULA DEGENERATION; RETINA MACULA EDEMA; REVIEW; STATISTICAL MODEL; VISUAL ACUITY;

DIABETIC RETINOPATHY; HEALTH STATUS; HEALTH STATUS INDICATORS; HUMANS; MACULAR DEGENERATION; MACULAR EDEMA; MODELS, ECONOMIC; MODELS, STATISTICAL; VISUAL ACUITY;

EID: 84888773229     PISSN: None     EISSN: 14712415     Source Type: Journal    
DOI: 10.1186/1471-2415-13-74     Document Type: Review

References (45)

1. Measurement of health state utilities for economic appraisal. Torrance GW, J Health Econ 1986 5 1 30 (Pubitemid 16098443)
2. Drummond MF, Sculpher MJ, O'Brien BJ, Stoddart GL, Methods for the Economic Evaluation of Health Care Programmes Oxford: Oxford University Press 3 2005
3. Brazier J, Ratcliffe J, Tsuchiya A, Measuring and Valuing Health Benefits for Economic Evaluations Oxford: Oxford University Press 2007
4. Modeling valuations for EuroQol health states. Dolan P, Med Care 1997 35 1095 1108 (Pubitemid 127453463)
5. The estimation of a preference-based measure of health from the SF-36. Brazier J, Roberts J, Deverill M, J Health Econ 2002 21 271 292 (Pubitemid 34143147)
6. Multi-attribute health status classification systems. Health utilities index. Feeny D, Furlong W, Boyle M, Torrance GW, Pharmacoeconomics 1995 7 490 502
7. Developing and testing methods for deriving preference-based measures of health from condition-specific measures (and other patient-based measures of outcome). Brazier JE, Rowen D, Mavranezouli I, Tsuchiya A, Young T, Yang Y, et al. Health Technol Assess 2012 16 1 114
8. Estimating a preference-based index for a 5-dimensional health state classification for asthma derived from the asthma quality of life questionnaire. Yang Y, Brazier JE, Tsuchiya A, Young TA, Med Decis Making 2011 31 281 291
9. Comparison of generic, condition-specific, and mapped health state utility values for multiple myeloma cancer. Rowen D, Young T, Brazier J, Gaugris S, Value Health 2012 15 1059 1068
10. Development of DEMQOL-U and DEMQOL-PROXY-U: generation of preference-based indices from DEMQOL and DEMQOL-PROXY for use in economic evaluation. Mulhern B, Rowen D, Brazier J, Smith S, Romeo R, Tait R, et al. Health Technol Assess 2013 17 22-140
11. National Institute for Health and Care Excellence, Guide to Methods of Technology Appraisals London 2013 http://www.nice.org.uk/media/D45/1E/ GuideToMethodsTechnologyAppraisal2013.pdf Last accessed 21st August 2013
12. The quality of life impact of peripheral versus central vision loss with a focus on glaucoma versus age-related macular degeneration. Evans K, Law SK, Walt J, Buchholz P, Hansen J, Clin Ophthalmol 2009 3 433 445
13. The impact of diabetic retinopathy and diabetic macular edema on health-related quality of life in type 1 and type 2 diabetes. Fenwick EK, Xie J, Ratcliffe J, Pesudovs K, Finger RP, Wong TY, et al. Invest Ophthalmol Vis Sci 2012 53 677 684
14. A review of generic preference-based measures of health-related quality of life in visual disorders. Tosh J, Brazier J, Evans P, Longworth L, Value Health 2012 15 118 127
15. NICE DSU Technical Support Document 9: The identification, review and synthesis of health state utility values from the literature. Papaioannou D, Brazier J, Paisley S, http://www.nicedsu.org.uk/TSD9%20HSUV%20values-FINAL.pdf. 2010 Last accessed 20th August 2013
16. Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration. Brown MM, Brown GC, Sharma S, Landy J, Bakal J, Arch Ophthalmol 2002 120 481 484 (Pubitemid 34727820)
17. Visual acuity measurement standard. International Council of Ophthalmology, 1998 http://www.icoph.org/resources/47/Visual-Acuity-Measurement- Standard.html Last accessed 3rd May 2013
18. Calculating the exact pooled variance. Rudmin JW, 2010 http://arxiv.org/ftp/arxiv/papers/1007/1007.1012.pdf ] Last accessed 3rd May 2013
19. Quality of life and relative importance: a comparison of time trade-off and conjoint analysis methods in patients with age-related macular degeneration. Aspinall PA, Hill AR, Dhillon B, Armbrecht AM, Nelson P, Lumsden C, et al. Br J Ophthalmol 2007 91 766 772 (Pubitemid 46846648)
20. Validity of EuroQOL-5D, time trade-off, and standard gamble for age-related macular degeneration in the Singapore population. Au Eong KG, Chan EW, Luo N, Wong SH, Tan NW, Lim TH, et al. Eye (Lond) 2012 26 379 388
21. Valuing condition-specific health states using simulation contact lenses. Czoski-Murray CC, Value in Health 2009 12 793 799
22. The impact of age-related macular degeneration on health status utility values. Espallargues M, Czoski-Murray CJ, Bansback NJ, Carlton J, Lewis GM, Hughes LA, et al. Invest Ophthalmol Vis Sci 2005 46 4016 4023 (Pubitemid 44264600)
23. The impact of anchor point on utilities for 5 common ophthalmic diseases. Lee BS, Kymes SM, Nease RFJ, Sumner W, Siegfried CJ, Gordon MO, Ophthalmology 2008 115 898 903
24. Health utility values associated with diabetic retinopathy. Lloyd A, Nafees B, Gavriel S, Rousculp MD, Boye KS, Ahmad A, Diabet Med 2008 25 618 624 (Pubitemid 351590891)
25. Verteporfin photodynamic therapy cohort study: report 2: Clinical measures of vision and health-related quality of life. Reeves BC, Langham J, Walker J, Grieve R, Chakravarthy U, Tomlin K, et al. Ophthalmology 2009 116 2463 2470
26. Health-related quality of life and utility in patients with age-related macular degeneration. Sahel JA, Bandello F, Augustin A, Maurel F, Negrini C, Berdeaux GH, et al. Arch Ophthalmol 2007 125 945 951 (Pubitemid 47076434)
27. Utilities associated with diabetic retinopathy: results from a Canadian sample. Sharma S, Oliver-Fernandez A, Bakal J, Hollands H, Brown GC, Brown MM, Br J Ophthalmol 2003 87 259 261 (Pubitemid 36307893)
28. Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study. Soubrane G, Cruess A, Lotery A, Pauleikhoff D, Mones J, Xu X, et al. Arch Ophthalmol 2007 125 1249 1254 (Pubitemid 47403034)
29. Utility values in Japanese patients with exudative age-related macular degeneration. Yanagi Y, Ueta T, Obata R, Iriyama A, Fukuda T, Hashimoto H, et al. Jpn J Ophthalmol 2011 55 35 38
30. Vision and quality-of-life. Brown GC, Trans Am Ophthalmol Soc 1999 97 473 511 (Pubitemid 30106064)
31. Quality of life associated with unilateral and bilateral good vision. Brown MM, Brown GC, Sharma S, Busbee B, Brown H, Ophthalmology 2001 108 643 647 (Pubitemid 32238453)
32. Quality of life associated with visual loss: a time tradeoff utility analysis comparison with medical health states. Brown MM, Brown GC, Sharma S, Busbee B, Ophthalmology 2003 110 1076 1081 (Pubitemid 36676636)
33. TTO utility scores measure quality of life in patients with visual morbidity due to diabetic retinopathy or ARMD. Shah VA, Gupta SK, Shah KV, Vinjamaram S, Chalam KV, Ophthalmic Epidemiol 2004 11 43 51 (Pubitemid 38367078)
34. Validity of the time trade-off and standard gamble methods of utility assessment in retinal patients. Sharma S, Brown GC, Brown MM, Hollands H, Robins R, Shah GK, Br J Ophthalmol 2002 86 493 496 (Pubitemid 34454489)
35. A utility analysis correlation with visual acuity: methodologies and vision in the better and poorer eyes. Brown MM, Brown GC, Sharma S, Smith AF, Landy J, Int Ophthalmol 2001 24 123 127 (Pubitemid 35446388)
36. Dollars may not buy as many QALYs as we think: a problem with defining quality-of-life adjustments. Fryback DG, Lawrence WF Jr, Med Decis Making 1997 17 276 284 (Pubitemid 27282028)
37. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: systematic review, statistical modelling and survey. Longworth L, Yang Y, Young T, Mulhern B, Hernandez Alva M, Mukuria C, et al. Health Technol Assess Monogr Ser 2013 In press
38. Solem C, Pickard A, Identification of Diseases for EQ-5D Bolt-On Items/Dimension Extensions Development: An Empirical Approach http://download.journals.elsevierhealth.com/pdfs/journals/1098-3015/ PIIS1098301511026325.pdf Last accessed 16th December 2013.
39. Rasch analysis in the development of a simplified version of the National Eye Institute Visual-Function Questionnaire-25 for utility estimation. Kowalski JW, Rentz AM, Walt JG, Lloyd A, Lee J, Young TA, et al. Qual Life Res 2012 21 323 334
40. National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS): AREDS Report No. 10. Clemons TE, Chew EY, Bressler SB, McBee W, Arch Ophthalmol 2003 121 211 217 (Pubitemid 36184034)
41. Development of the 25-item National Eye Institute Visual Function Questionnaire. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD, Arch Ophthalmol 2001 119 1050 1058 (Pubitemid 32652197)
42. The NEI-VFQ-25 in people with long-term type 1 diabetes mellitus: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Klein R, Moss SE, Klein BE, Gutierrez P, Mangione CM, Arch Ophthalmol 2001 119 733 740 (Pubitemid 32417380)
43. The National Eye Institute Visual Function Questionnaire: experience of the ONTT. Optic neuritis treatment trial. Cole SR, Beck RW, Moke PS, Gal RL, Long DT, Invest Ophthalmol Vis Sci 2000 41 1017 1021 (Pubitemid 30187536)
44. Responsiveness of the National Eye Institute Visual Function Questionnaire to changes in visual acuity: findings in patients with subfoveal choroidal neovascularization-SST Report No. 1. Miskala PH, Hawkins BS, Mangione CM, Bass EB, Bressler NM, Dong LM, et al. Arch Ophthalmol 2003 121 531 539 (Pubitemid 36427640)
45. Visual impairment, visual functioning, and quality of life assessments in patients with glaucoma. Parrish RK, Trans Am Ophthalmol Soc 1996 94 919 1028